Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Processa Pharmaceuticals, Inc. - Common Stock (NQ: PCSA )

0.5238 -0.0062 (-1.17%)
Streaming Delayed Price Updated: 2:02 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Processa Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Reports Phase 2 Clinical Trial Dosing Has Commenced
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference, ESMO Congress 2024
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q2 2024 Financial Results, Provides Updates
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Positive Data from Two Preclinical Studies of NGC-Iri
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) IND Application for Phase 2 Clinical Trial of NGC-Cap in Patients with Breast Cancer Receives FDA Clearance
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Seasoned Veteran as Chief Financial Officer
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Positive Efficacy Results from Phase 1b Trial
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at Upcoming EF Hutton Global Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Appoints Dr. Steven Cha to Lead Clinical Development of Oncology Programs
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Presents New Data from NGC-Cap Phase 1b Trial at AACR Annual Meeting
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming MedInvest Conference
Via Investor Brand Network
Exposures Product Safety
TinyGemsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming MedInvest Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at American Association for Cancer Research Annual Meeting
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at 2024 BIO CEO & Investor Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes on $7M Public Offering
Via Investor Brand Network
Exposures Product Safety
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
Via AB Newswire
Topics Retirement
Exposures Pension
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Pricing Information for $7M Public Offering
Via Investor Brand Network
Exposures Product Safety
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
From Processa Pharmaceuticals, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Completes Phase 1b Safety Evaluation of NGC-Cap
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Plans to Expand NGC-Cap Program into Advanced or Metastatic Breast Cancer
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces 1-for-20 Reverse Stock Split
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Biotech Showcase 2024
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Provides Interim Analysis from Phase 1b NGC-Cap Trial
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Gains Helpful Guidance on Overall Design of NGC-Cap Phase 2 Study
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in December MedInvest Oncology Investor Conference
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Shareholder Letter
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Reports Unexpected Passing of Board Member
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming Orphan Drugs and Rare Diseases Global Congress
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Creates Advisory Board, Names Renowned Experts as Members
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at Upcoming ThinkEquity Conference
Via Investor Brand Network
Exposures Product Safety
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.